Clinical Trial: Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07599995) titled 'Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies' on April 28.

Brief Summary: This trial is to evaluate the efficacy of Gemcitabine-Cisplatin (GC) plus Envafolimab neoadjuvant therapy in the patients at high risk of recurrence. Primary endpoint: Major Pathologic Response (MPR). It will also learn about the safety of drug including Gemcitabine-Cisplatin (GC) plus Envafolimab as a neoadjuvant therapy in this trial.

Study Start Date: May 30

Study Type: INTERVENTIONAL

Condition: Biliary Tract Cancer

Intervention: DRUG: Neoadjuvant therapy followed by surgery

First:

Envafolimab: 400 mg on Day 1, repe...